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Matt P Wise1, Janneke Horn2, Anders Åneman3 and Niklas Nielsen4,5*Targeted temperature management was adopted as part
of the treatment of unconscious survivors of out-of-
hospital cardiac arrest following the publication of two
landmark studies [1,2] which concluded that mild in-
duced hypothermia (32°C to 34°C) improved survival
and neurological outcome, substantiating the neuropro-
tective effect of mild hypothermia described in experi-
mental animal data [3]. Subsequently, this therapy was
recommended by international guidelines [4,5] and be-
came a standard of care. Although both trials [1,2] had
exclusion criteria limiting generalizability, mild induced
hypothermia was applied to the wider cardiac arrest
population.
Until recently [6], despite uncertainties over what rep-
resents the optimal target population, temperature, dur-
ation of therapy, or rate of rewarming [5], no large
randomized clinical trials (RCTs) had been conducted
since 2003. A systematic review and meta-analysis per-
formed by using the Grading of Recommendations
Assessment, Development, and Evaluation system [7]
and trial sequential analysis [8] concluded that the existing
quality of evidence was low and that firm evidence in sup-
port of induced hypothermia was lacking [9].
To further investigate targeted temperature manage-
ment, the Target Temperature Management (TTM) after
out-of-hospital cardiac arrest trial group was established.
As mild induced hypothermia had become ingrained in
clinical practice, it was considered infeasible to compare
32°C to 34°C with no temperature control, as failing to
control fever would have been unacceptable to many cli-
nicians. The primary objective of the TTM trial [6] was
to compare 33°C with 36°C in unconscious survivors of* Correspondence: niklas.nielsen@telia.com
4Department of Anesthesiology and Intensive Care, Helsingborg Hospital, S
Vallgatan 5, S-25187 Helsingborg, Sweden
5Department of Clinical Sciences, Lund University, Box 117, S-22100 Lund,
Sweden
Full list of author information is available at the end of the article
© 2014 Wise et al., licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.out-of-hospital cardiac arrest for survival for a minimum
follow-up of 6 months. A temperature of 36°C was
chosen as registry data showed that 36°C was the me-
dian temperature of out-of-hospital cardiac arrest pa-
tients arriving at the hospital. Furthermore, it was
unlikely that, if feedback-controlled cooling devices were
used, the temperature in the 36°C group would stray into
the febrile range.
The TTM trial sought to be pragmatic, reflecting
current clinical practice [10] of applying mild induced
hypothermia to the entire out-of-hospital cardiac arrest
population. Arrests of a presumed cardiac cause of all
rhythms, including witnessed asystole, were included, as
neuroprotection should not depend on initial rhythm.
The trial protocol and analysis plan were published in
advance and attempted to address possible deficiencies
of previous trials [10,11]. These included the following: a
sample size twice as large as all previous RCTs combined
(939 versus 478) adequately powered to detect or reject
differences in survival, documentation of coma level at
randomization, avoidance of hyperthermia both during
and after completion of target temperature manage-
ment in unconscious patients, standardized neurological
assessment/prognostication, and guidance for withdrawal
of treatment (adverse events, including infections, bleed-
ing, electrolyte disturbances, seizures, and arrhythmias,
were also recorded); a blinded neurological follow-up
[10,12] extending beyond crude scales (Cerebral Perform-
ance Category and modified Rankin Scale), including tests
on quality of life and cognitive function assessing both sur-
vivors and relatives in a face-to-face visit in the majority;
and a bio-bank of approximately 20,000 blood samples to
investigate the role of biomarkers.
The results of the TTM trial were unequivocal, dem-
onstrating no difference in survival or the secondary
outcome of combined survival and neurological out-
come [6]. An important design feature of the TTM
trial, distinguishing it from earlier trials, was the approachd. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Mean bladder temperature in the 33°C and 36°C
intervention groups of the Target Temperature Management
trial, during the 36 hours of temperature intervention. The
temperature graph in the initial publication [6] showed mean
body temperature with a dispersion of two standard deviations
encompassing 95% of all observations. Temperature values are
presented with 95% confidence intervals.
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remaining unconscious [13,14]. Prognostication was de-
layed for 108 hours (unless specific withdrawal criteria
were met) and performed by a clinician who was blinded
to the intervention and who then recommended with-
drawal, continuation, or no further escalation of care.
The robust design of the TTM trial has been recog-
nized by a number of commentators [13,14], including
an author of one of the landmark trials [2]. However,
others have questioned the validity of the study, raising
concerns over the rate of rewarming, temperature separ-
ation and swings, and recruitment rates [15]. It has been
argued that the rate of rewarming was rapid, abrogating
the benefits of cooling to 33°C [15]. The optimal rate of
rewarming remains unknown [5] but was undertaken at
a maximum speed of 0.5°C per hour in keeping with
current guidelines [5]. The actual rewarming rate in the
TTM trial was 0.36 ± 0.13°C per hour, which seems com-
parable to the rate in the Hypothermia after Cardiac
Arrest trial [1], and the two temperature arms were
clearly well controlled and separated (Figure 1). The
TTM trial aimed to reflect current clinical practice, in-
cluding as large a population as possible to make the re-
sults applicable to use by clinicians. On the basis of
registries, 80% of patients meeting inclusion criteria in
the TTM trial would be eligible for random assignment
after exclusion criteria were considered [16]. The 66%
screening to inclusion (and 76% random assignment of
patients meeting inclusion criteria) represents a consid-
erable effort by participating sites. Although the study
ran more than 26 months, it was not until 9 months
that 50% of sites were open to recruitment. The mediannumber of patients randomly assigned per site was 21, and
sites above the median recruited 80% of all patients.
In this trial (the largest one to date), there was no dif-
ference in outcomes between unconscious survivors of
out-of-hospital cardiac arrest treated at 33°C or 36°C,
giving clinicians the option of choosing either temperature
management strategy, but the least invasive strategy is
compelling [13]. The most interesting aspect of the TTM
trial may be that it indicates substantial knowledge gaps in
post-cardiac arrest fever and temperature management.
The optimal temperature, duration of temperature man-
agement, and target population remain to be defined.Abbreviations
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